A prolonged West Asia conflict could trim corporate operating profitability by roughly 200 basis points in FY27, according to a Crisil Ratings stress test of 34 sectors released on Monday. The stress test assumes nine months of supply-chain disruption and crude oil averaging $110 a barrel, compared to six months in the base-case scenario. These sectors together account for 65% of its rated corporate debt. Of the 34 sectors, 22 would see profitability cut by more than a tenth (medium/high margin impact) as higher inventory and freight costs prove hard to pass on immediately. India Inc's operating profitability could decline to around 10% this fiscal from the pre-conflict expectation of nearly 12%, with some sectors expected to witness sharper stress. As per Crisil Ratings, the protracted conflict has pushed domestic companies to realign supply chains, navigate pricing issues, absorb higher fuel and freight costs, and contend with a depreciating rupee. Managing Director of Crisil, Subodh Rai, said the bigger challenge will be on costs, noting that for companies, managing costs and profitability will be a bigger challenge than achieving topline growth. The agency has also revised its crude oil price assumption to $110 per barrel this fiscal from its earlier estimate of $95 per barrel.
Sun Pharma has become the latest pharmaceutical company to flag West Asia conflict risks, with the company prioritizing operational resilience over numerical forecasts as the conflict drives up shipping expenses. The company, which maintains operating margins in the 26-28% range historically, is absorbing higher shipping costs, which may compress the 26% EBITDA baseline in the short term. Sun Pharma's specialty segment contributes approximately 18% of total revenue, but the company is shifting from providing annual margin guidance to a 'no-guidance' stance due to macro volatility. The company's large-scale global distribution network makes it particularly sensitive to maritime disruptions in the Suez Canal and surrounding regions. Sun Pharma's institutional holding may remain stable given its strong cash reserves, but retail sentiment could turn cautious regarding near-term earnings beats. The company recently completed the integration of Taro Pharmaceutical Industries and received US FDA approval for its new alopecia treatment, though recent inspections at the Dadra facility resulted in minor procedural observations.
The stress test reveals significant sector-specific vulnerabilities beyond the overall margin impact. Ceramics emerges as the hardest hit sector, with revenue potentially down by a third and profit halved due to gas shortages. Airlines, polyester textiles, specialty chemicals, flexible packaging, auto components, diamond polishers and basmati rice also show moderate negative impact on their credit quality. The airline sector is likely to be affected by airspace closures, higher aviation fuel costs and rupee depreciation, with profitability potentially declining by around 50%. Crude-linked industries such as polyester textiles, specialty chemicals and flexible packaging manufacturers are expected to face pressure because of delayed pass-through of higher raw material costs. Auto component manufacturers could see lagged recovery of increased production and freight costs, particularly in the aftermarket segment. Diamond polishers may face higher procurement costs because of sourcing disruptions through alternative hubs, while basmati rice exporters could see lower offtake from key overseas markets. Seven sectors are expected to witness a moderately negative impact on credit quality, mainly due to pressure on operating margins.
Tata Steel has been significantly impacted by the conflict, with about 70-80% of limestone sourced from West Asia used in the steelmaking process. As reported by Business Standard, the company is now procuring it from Vietnam, India, and other ASEAN countries, apart from Oman, bypassing the Strait of Hormuz. The company's variable costs have increased by about 10% due to rising freight, insurance, and propane costs. Eicher Motors and Bajaj Auto have partly mitigated the impact through price increases, with Eicher Motors taking 1.75% price offset in Royal Enfield and 2% in VE Commercial Vehicles.
The pharma industry faces significant challenges from the West Asia disruption, with Sun Pharma's decision to withhold margin guidance a conservative but prudent move to manage market expectations. Prices of key APIs from China, including paracetamol, have risen since the crisis began, with paracetamol prices nearly doubling in recent months. Azithromycin API prices have also surged, with some categories seeing price increases of 30-40%. India holds about two months of API stock, and industry representatives have raised concerns with the government over solvent supply continuity. The Indian pharmaceutical industry, which accounts for over 20% of global generic exports by volume, is currently navigating a twin challenge: US FDA regulatory stringency and escalating maritime logistics costs. Competitors like Dr. Reddy's and Cipla are also monitoring the Red Sea and West Asia situation closely, as freight costs have historically spiked by 30-50% during similar geopolitical crises. Currency volatility impacting landed costs of raw materials (APIs) adds to the sector's challenges.
